Carolyn R. Bertozzi Biography, Age, Height, Husband, Net Worth, Family

Age, Biography and Wiki

Carolyn R. Bertozzi was born on 10 October, 1966 in Boston, Massachusetts, United States, is an American chemist (born 1966). Discover Carolyn R. Bertozzi's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is She in this year and how She spends money? Also learn how She earned most of networth at the age of 57 years old?

We recommend you to check the complete list of Famous People born on 10 October. She is a member of famous with the age 57 years old group.

Carolyn R. Bertozzi Height, Weight & Measurements

At 57 years old, Carolyn R. Bertozzi height not available right now. We will update Carolyn R. Bertozzi's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Dating & Relationship status

She is currently single. She is not dating anyone. We don't have much information about She's past relationship and any previous engaged. According to our Database, She has no children.

Carolyn R. Bertozzi Net Worth

Her net worth has been growing significantly in 2022-2023. So, how much is Carolyn R. Bertozzi worth at the age of 57 years old? Carolyn R. Bertozzi’s income source is mostly from being a successful . She is from United States. We have estimated Carolyn R. Bertozzi's net worth , money, salary, income, and assets.

Carolyn R. Bertozzi Social Network

Timeline

Bertozzi studies the glycobiology of underlying diseases such as cancer, inflammatory disorders such as arthritis, and infectious diseases such as tuberculosis. In particular, Bertozzi has advanced the understanding of cell surface oligosaccharides involved in cell recognition and inter-cellular communication. Bertozzi has applied the techniques of bioorthogonal chemistry to study glycocalyx, the sugars that surround the cell membrane. Her discoveries have advanced the field of biotherapeutics. Her lab has also developed tools for research. One such development is creating chemical tools for studying glycans in living systems. Her lab's development of nanotechnologies which probe biological systems lead to the development of a fast point-of-care tuberculosis test in 2018. In 2017, due to her lab's discovery of linking the sugars on the surface of cancer cells and their ability to avoid the immune system defenses, she was invited to speak at Stanford's TED talk, giving a talk entitled What the sugar coating on your cells is trying to tell you.

In addition to her academic work, Bertozzi works actively with biotechnology start-ups. She has served on the research advisory board of GlaxoSmithKline. In the early 2000s, Bertozzi and Steve Rosen co-founded Thios Pharmaceuticals the first company to target sulfation pathways. In 2008, Bertozzi founded a startup of her own: Redwood Bioscience of Emeryville, California. Redwood Bioscience is a biotechnology company that uses SMARTag, a site-specific protein modification technology that allows small drugs to attach to sites on the proteins and can be used to help fight cancers. Redwood Bioscience was acquired by Catalent Pharma Solutions in 2014. Bertozzi remains a part of the advisory board for the biologics sector of the company. In 2014, she co-founded Enable Biosciences which focuses on biotechnologies for at-home diagnoses for type 1 diabetes, HIV, and other diseases. Bertozzi became a co-founder of Palleon Pharma of Waltham, Massachusetts in 2015. Palleon Pharma focuses on investigating glycoimmune checkpoint inhibitors as a potential treatment for cancer. In 2017, Bertozzi helped found InterVenn Biosciences, which uses mass spectrometry and artificial intelligence to enhance glycoproteomics for target and biomarker discovery, ovarian cancer diagnostics, and predicting the successes and failures of clinical trials. She co-founded Grace Science Foundation in 2018. The foundation focuses on curing NGLY1 deficiency through developing therapeutics that are efficient and inexpensive. In 2019 she co-founded both OliLux Biosciences and Lycia Therapeutics. OliLux Biosciences develops new methods for tuberculosis detection. The founding of Lycia Therapeutics occurred when Bertozzi's group discovered lysosome-targeting chimeras (LYTACs). The new molecule class may be able to degrade some cardiovascular disease and cancer targets. Lycia Therapeutics focuses on developing technology which utilizes lysosome-targeting chimeras (LYTACs).

Bertozzi joined the UC Berkeley faculty in 1996. She has been an investigator with HHMI since 2000. In 1999, while working with HHMI and at UC Berkeley, she founded the field of bioorthogonal chemistry and coined the term in 2003. This new field and technique allows researchers to chemically modify molecules in living organisms and not interrupt the processes of the cell. In 2015, Bertozzi moved to Stanford University to join the ChEM-H Institute.

Bertozzi completed her Ph.D. in Chemistry at UC Berkeley in 1993 with Professor Mark Bednarski, working on the chemical synthesis of oligosaccharide analogs. While working under Professor Bednarski, she discovered that viruses can bind to sugars in the body. The discovery led her to her current field of research glycobiology. After completing a Ph.D., Bertozzi was a postdoctoral fellow at UCSF with Professor Steven Rosen, where she studied the activity of endothelial oligosaccharides in promoting cell adhesion at inflammation sites. While working with Professor Rosen, Bertozzi was able to modify the protein and sugar molecules in the walls of living cells so that the cells accept foreign materials such as implants.

Carolyn Ruth Bertozzi (born October 10, 1966) is an American chemist. Bertozzi is known for founding a new field of chemistry: bioorthogonal chemistry. At Stanford University, she holds the Anne T. and Robert M. Bass Professorship in the School of Humanities and Sciences. Bertozzi is also an Investigator at the Howard Hughes Medical Institute (HHMI) and is the former Director of the Molecular Foundry, a nanoscience research center at Lawrence Berkeley National Laboratory. She received the MacArthur "genius" award at age 33. In 2010, she was the first woman to receive the prestigious Lemelson-MIT Prize faculty award. She is a member of the National Academy of Sciences (2005), the Institute of Medicine (2011), and the National Academy of Inventors (2013). In 2014, it was announced that Bertozzi would lead ACS Central Science, the American Chemical Society's first peer-reviewed open access journal that offers all content free to the public.